/
BMRN
$57.41-$0.27 (-0.46%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$11.4B
193M shares
52-week range
$49.26 – $66.28
48% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.39%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-26.50
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.70B | $1.86B | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B |
| Cost of revenue | $315.3M | $359.5M | $524.3M | $470.5M | $503.0M | $532.1M | $580.2M | $736.8M |
| Gross profit | $1.18B | $1.34B | $1.34B | $1.38B | $1.59B | $1.89B | $2.27B | $2.48B |
| Gross margin | 78.9% | 78.9% | 71.8% | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| R&D | $696.3M | $715.0M | $628.1M | $628.8M | $649.6M | $746.8M | $747.2M | $921.9M |
| Operating income | −$123.5M | −$100.5M | −$43.4M | −$82.3M | $161.0M | $185.8M | $484.2M | $533.5M |
| EBITDA | −$3.4M | $31.9M | $83.7M | $47.4M | $265.4M | $306.8M | $650.5M | $572.9M |
| Net income | −$77.2M | −$23.8M | $854.0M | −$64.1M | $141.6M | $167.6M | $426.9M | $348.9M |
| Net margin | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (diluted) | -0.44 | -0.13 | 4.53 | -0.35 | 0.75 | 0.88 | 2.21 | 1.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.9B | $4.94 | $4.85–$5.03 | 16 |
| 2027 | $4.5B | $6.57 | $4.90–$7.74 | 15 |
| 2028 | $4.8B | $7.63 | $4.03–$10.85 | 14 |
| 2029 | $5.1B | $8.43 | $8.09–$9.55 | 8 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$8.63
Price
$57.41
Implied downside
-85%
Peer comparison
BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
www.biomarin.com- Employees
- 3,221
- IPO / List date
- Jul 23, 1999
- HQ
- NOVATO, CA
Held by traders on TradeandTell
No one on the platform currently holds BMRN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,024,871 | $57.9M |
| Bridgewater Associatesas of 2026-03-31 | 206,911 | $11.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BMRN yet.
